ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer 

ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer 

2025.11.05
At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.
CSCO Experts’ Insights │ Professor Fangjian Zhou: Guideline Updates and Quality Control System Drive China’s Renal Cancer Care to the Global Forefront

CSCO Experts’ Insights │ Professor Fangjian Zhou: Guideline Updates and Quality Control System Drive China’s Renal Cancer Care to the Global Forefront

2025.11.03
From September 10 to 14, 2025, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, Shandong. With the theme “Standardizing Diagnosis and Treatment, Leading Innovation”, the conference brought together leading domestic and international scholars. The Renal Cancer session featured the highly anticipated release of the 2025 CSCO Renal Cancer Guidelines, setting a new standard for improving treatment outcomes and promoting standardized care across China. Following the conference, Oncology Frontier – Urology Frontier invited Professor Fangjian Zhou from Sun Yat-sen University Cancer Center to discuss the groundbreaking advances in renal cancer management and the quality-control experience of the Guangdong Cancer Center.
Transformative Advances in mHSPC Treatment Strategies

Transformative Advances in mHSPC Treatment Strategies

2025.11.03
Editor’s Note: On August 22–23, 2025, the highly anticipated 2025 Pujiang Uro-Oncology Conference was held in Shanghai, gathering leading experts in urologic oncology from across China and abroad. Among the key topics was the optimization of treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC). Professor Xinan Sheng from Peking University Cancer Hospital delivered an insightful lecture titled “The Combination Revolution in mHSPC — Multi-Strategy Optimization of Patient Management.” His talk provided a systematic review of the current treatment landscape, key challenges, and future directions for mHSPC management.
Professor Fang Liu: Unveiling the Application and Future Prospects of CAR-T Therapy in Acute Myeloid Leukemia丨13th Lu Daopei Hematology Conference

Professor Fang Liu: Unveiling the Application and Future Prospects of CAR-T Therapy in Acute Myeloid Leukemia丨13th Lu Daopei Hematology Conference

2025.11.02
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease Foundation, and hosted by the Beijing Lu Daopei Hematology Institute. The conference gathered world-leading hematology experts and focused on hematopoietic stem cell transplantation, cellular therapy, and precision treatment of hematologic malignancies. With over a thousand participants, the meeting provided a high-level and in-depth academic exchange. During the conference, Professor Fang Liu from Shanghai Xindaobei Hematology Hospital delivered a presentation on the latest clinical advances of CAR-T therapy in acute myeloid leukemia (AML). Oncology Frontier – Hematology News invited Professor Liu to elaborate on the core clinical issues, offering important insights to guide optimized management strategies.